

Prior Authorization DRUG Guidelines

CETROTIDE® (Cetrorelix)

Effective Date: 7/28/05

Date Developed: 7/14/05 by C. Wilhelmy MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20,
8/3/21, 2/1/22, 1/31/23, 2/13/24, 2/18/25

Cetrotide is a Gonadotropin Releasing Hormone Antagonist. It competes with naturally occurring GnRH for binding on receptors of the pituitary. This delay luteinizing hormone surge, preventing ovulation until the follicles are of adequate size.

Pre-Authorization Criteria:

Controlled ovarian stimulation: Inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation

Note:

VCHCP requires that Cetrotide be prescribed by an infertility specialist and ultrasound monitoring to assess follicle size

DOSING: ADULTS

Controlled ovarian stimulation in conjunction with gonadotropins

(FSH, hMG): Female: SubQ: 0.25 mg once daily the morning or evening of stimulation day 5, or morning of stimulation day 6; continue 0.25 mg once daily until the day hCG is administered.

NOTE: Not intended for use in women over 65 years of age. Not recommended for women with severe allergic conditions Contraindicated with severe kidney impairment,

pregnancy and concomitant use of gonadotropin releasing hormone (GnRH) or GnRH analogs.

REFERENCES

1. Cetrotide (cetorelix acetate) [prescribing information]. Rockland, MA: EMD Serono, Inc; May 2018.
2. Cetrotide (cetorelix acetate) [product monograph]. Mississauga, Ontario, Canada: EMD Serono; June 2019.
3. UpToDate: Cetorelix
4. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.

Revision History:

Date Reviewed/Updated: 10/17/11 by A. Reeves MD

Date Reviewed/No Updates: 4/2/12; 1.16.13 by A. Reeves MD

Date Approved by P&T Committee: 7/28/05; 10/25/11; 4/24/12; 1/29/13 Date Reviewed/No Updates: 1/28/14 by C. Sanders MD

Date Approved by P&T Committee: 1/28/14

Date Reviewed/Updated: 2/17/15 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 8/3/21

Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/1/22

Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/31/23

Date Reviewed/No Updates: 2/13/24 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/13/24

Date Reviewed/Updated: 2/18/25 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/25

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated Precautions Section, References, and formatting.
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/13/24	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
2/18/25	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated dosing in elderly. Removed dosing: renal impairment, administration, contraindications precautions, pregnancy, lactation and patient education sections